Novaliq is an ophthalmic pharmaceutical company based in Heidelberg, Germany with an office in Cambridge, U.S.
Novaliq’s mission is to transform ocular therapeutics based on EyeSol® the first and only water-free technology, enhancing the topical bio-availability, stability and safety of traditionally insoluble or unstable drugs.
Novaliq has developed a tiered portfolio of differentiated products addressing the needs of eye patients:
NovaTears® which improves the signs and symptoms of dry eye disease (DED) is marketed under CE-approval in Australia/NewZealand by AFT Pharmaceuticals and in Europe as EvoTears® by Ursapharm.
Two prescription drugs are in late stage clinical development:
- CyclASol®, an anti-inflammatory and immunomodulating drug for the treatment of DED with a demonstrated early onset of action and excellent tolerability, is evaluated in the pivotal ESSENCE phase 2b/3 trial.
- NOV03, the first drug addressing evaporative DED associated with meibomian gland dysfunction (MGD), is evaluated in the SEECASE phase 2 trial. Results for both U.S. trials are anticipated in Q3 2018.
Set your eyes on the future – contact us!
Schedule your appointment now!
Contact us today